Minoryx Therapeutics
Barcelona, Spain · Health and Medical
This profile has not been verified by the business owner.
Information may be incomplete or outdated.
Overview
Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million
Contact Details
info@minoryx.com
Barcelona, Spain
+1
Founded
2011
Company Type
Private Limited Company
Employees
30-50
Keywords
#rare diseases
#neurometabolic diseases
#x-linked adrenoleukodystrophy
#friedreich's ataxia
#orphan cns
Companies teams usually look at after Minoryx Therapeutics
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.